Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.
Celltrion Inc.’s Truxima became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.
Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.
China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.
A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said.
The Janssen Pharmaceutical Companies of J&J announced the U.S. FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia.
Celgene Reports Promising Data For Revlimid-Rituximab Combination For Relapsed/Refractory Indolent Lymphoma
Celgene Corporation announced results from a phase III, randomized, double-blind, international clinical study AUGMENT showing that Revlimid (lenalidomide) plus rituximab (R2) achieved a highly statistically significant improvement in the primary endpoint of progression-free survival compared to rituximab plus placebo, in the final PFS analysis.
BeiGene Ltd. announced that the commercial-stage biopharmaceutical company’s investigational BTK inhibitor zanubrutinib was granted Fast Track designation by the U.S. FDA for the treatment of patients with Waldenström macroglobulinemia.